The anti-cancer properties of heparin and its derivatives: a review and prospect

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Casu B. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem. 1985;43:51–134.
   PubMed Web of Science ®Google Scholar
• Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–2135.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Khorana AA, Lyman GH, et al. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer. 2007;110:1149–1161.
   PubMed Web of Science ®Google Scholar
• Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266–1271.
   PubMed Web of Science ®Google Scholar
• Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol. 2007;95:507–512.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441–445.
   PubMed Web of Science ®Google Scholar
• Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130:800–809.
   PubMed Web of Science ®Google Scholar
• Yoshitomi Y, Nakanishi H, Kusano Y, et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett. 2004;207:165–174.
   PubMed Web of Science ®Google Scholar
• Borsig L, Wong R, Hynes RO, et al. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A. 2002;99:2193–2198.
   PubMed Web of Science ®Google Scholar
• Green D, Hull RD, Brant R, et al. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet. 1992;339:1476.
   PubMed Web of Science ®Google Scholar
• Hettiarachchi RJ, Smorenburg SM, Ginsberg J, et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost. 1999;82:947–952.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944–1948.
   PubMed Web of Science ®Google Scholar
• Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost. 2004;92:627–633.
   PubMed Web of Science ®Google Scholar
• Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003;112:853–862.
   PubMed Web of Science ®Google Scholar
• Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst. 1999;91:22–36.
   PubMed Web of Science ®Google Scholar
• Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98:3352–3357.
   PubMed Web of Science ®Google Scholar
• Stevenson JL, Varki A, Borsig L. Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res. 2007;120(Suppl 2):S107–11.
   PubMedGoogle Scholar
• Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer. 1994;74:38–45.
   PubMed Web of Science ®Google Scholar
• von Tempelhoff GF, Harenberg J, Niemann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol. 2000;16:815–824.
   PubMed Web of Science ®Google Scholar
• Heinmoller E, Schropp T, Kisker O, et al. Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol. 1995;30:1008–1016.
   PubMed Web of Science ®Google Scholar
• Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009;102:258–267.
   PubMed Web of Science ®Google Scholar
• Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53:93–105.
   PubMed Web of Science ®Google Scholar
• Achen MG, Mann GB, Stacker SA. Targeting lymphangiogenesis to prevent tumour metastasis. Br J Cancer. 2006;94:1355–1360.
   PubMed Web of Science ®Google Scholar
• Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell. 2010;140:460–476.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer. 2002;2:573–583.
   PubMed Web of Science ®Google Scholar
• Choi JU, Chung SW, Al-Hilal TA, et al. A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling pathway. Biomaterials. 2017;139:56–66.
   PubMed Web of Science ®Google Scholar
• He Y, Kozaki K, Karpanen T, et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst. 2002;94:819–825.
   PubMed Web of Science ®Google Scholar
• Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006;66:2650–2657.
   PubMed Web of Science ®Google Scholar
• Alam F, Al-Hilal TA, Chung SW, et al. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid. Biomaterials. 2014;35:6543–6552.
   PubMed Web of Science ®Google Scholar
• Yin W, Zhang J, Jiang Y, et al. Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice. Exp Ther Med. 2014;8:1213–1218.
   PubMed Web of Science ®Google Scholar
• Park J, Kim J-Y, Hwang SR, et al. Chemical Conjugate of Low Molecular Weight Heparin and Suramin Fragment Inhibits Tumor Growth Possibly by Blocking VEGF165. Mol Pharm. 2015;12:3935–3942.
   PubMedGoogle Scholar
• Kevane B, Egan K, Allen S, et al. Endothelial barrier protective properties of low molecular weight heparin: A novel potential tool in the prevention of cancer metastasis? Res Pract Thromb Haemost. 2017;1:23–32.
   PubMed Web of Science ®Google Scholar
• Al Nahain A, Ignjatovic V, Monagle P, et al. Anticoagulant heparin mimetics via RAFT polymerization. Biomacromolecules. 2020;21:1009–1021.
   PubMed Web of Science ®Google Scholar
• Alekseeva A, Mazzini G, Giannini G, et al. Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat. Carbohydr Polym. 2017;156:470–480.
   PubMed Web of Science ®Google Scholar
• Gomes AM, Kozlowski EO, Borsig L, et al. Antitumor properties of a new non-anticoagulant heparin analog from the mollusk Nodipecten nodosus: effect on P-selectin, heparanase, metastasis and cellular recruitment. Glycobiology. 2015;25:386–393.
   PubMed Web of Science ®Google Scholar
• Weissmann M, Bhattacharya U, Feld S, et al. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: mode of action. Matrix Biol. 2019;77:58–72.
   PubMed Web of Science ®Google Scholar
• Ferro V, Liu L, Johnstone KD, et al. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem. 2012;55:3804–3813.
   PubMed Web of Science ®Google Scholar
• Alyahya R, Sudha T, Racz M, et al. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. Int J Oncol. 2015;46:1225–1231.
   PubMed Web of Science ®Google Scholar
• Kansas GS. Selectins and their ligands: current concepts and controversies. Blood. 1996;88:3259–3287.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Borsig L, Varki NM, et al. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998;95:9325–9330.
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Boehme B, Podda M, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004;64:2743–2750.
   PubMed Web of Science ®Google Scholar
• Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol. 2010;20:169–177.
   PubMed Web of Science ®Google Scholar
• Laubli H, Spanaus KS, Borsig L. Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes. Blood. 2009;114:4583–4591.
   PubMed Web of Science ®Google Scholar
• Khatib AM, Kontogiannea M, Fallavollita L, et al. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res. 1999;59:1356–1361.
   PubMed Web of Science ®Google Scholar
• Brodt P, Fallavollita L, Bresalier RS, et al. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer. 1997;71:612–619.
   PubMed Web of Science ®Google Scholar
• Hostettler N, Naggi A, Torri G, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. Faseb J. 2007;21:3562–3572.
   PubMed Web of Science ®Google Scholar
• Sudha T, Phillips P, Kanaan C, et al. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model. Clin Exp Metastasis. 2012;29:431–439.
   PubMed Web of Science ®Google Scholar
• Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003;90:549–554.
   PubMed Web of Science ®Google Scholar
• Burdick MM, Konstantopoulos K. Platelet-induced enhancement of LS174T colon carcinoma and THP-1 monocytoid cell adhesion to vascular endothelium under flow. Am J Physiol Cell Physiol. 2004;287:C539–47.
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu Y, Gao Y, et al. Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo. Int J Cancer. 2009;125:2058–2065.
   PubMed Web of Science ®Google Scholar
• Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:676731.
   PubMedGoogle Scholar
• Schlesinger M, Simonis D, Schmitz P, et al. Binding between heparin and the integrin VLA-4. Thromb Haemost. 2009;102:816–822.
   PubMed Web of Science ®Google Scholar
• Schlesinger M, Naggi A, Torri G, et al. Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins. Int J Clin Pharmacol Ther. 2010;48:448–450.
   PubMed Web of Science ®Google Scholar
• Schlesinger M, Schmitz P, Zeisig R, et al. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives. Thromb Res. 2012;129:603–610.
   PubMed Web of Science ®Google Scholar
• von Delius S, Ayvaz M, Wagenpfeil S, et al. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost. 2007;98:434–439.
   PubMed Web of Science ®Google Scholar
• Handel TM, Johnson Z, Crown SE, et al. Regulation of protein function by glycosaminoglycans–as exemplified by chemokines. Annu Rev Biochem. 2005;74:385–410.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2010;16:2927–2931.
   PubMed Web of Science ®Google Scholar
• Benovic JL, Marchese A. A new key in breast cancer metastasis. Cancer Cell. 2004;6:429–430.
   PubMed Web of Science ®Google Scholar
• White FA, Bhangoo SK, Miller RJ. Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov. 2005;4:834–844.
   PubMed Web of Science ®Google Scholar
• Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004;35:233–245.
   PubMed Web of Science ®Google Scholar
• Kucia M, Ratajczak J, Ratajczak MZ. Bone marrow as a source of circulating CXCR4+ tissue-committed stem cells. Biol Cell. 2005;97:133–146.
   PubMed Web of Science ®Google Scholar
• Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879–894.
   PubMed Web of Science ®Google Scholar
• Simka M. Anti-metastatic activity of heparin is probably associated with modulation of SDF-1-CXCR4 axis. Med Hypotheses. 2007;69:709.
   PubMed Web of Science ®Google Scholar
• Harvey JR, Mellor P, Eldaly H, et al. Inhibition of CXCR4-mediated breast cancer metastasis: a potential role for heparinoids? Clinical cancer research: an official. J Am Ass Cancer Res. 2007;13:1562–1570.
   Google Scholar
• Mellor P, Harvey JR, Murphy KJ, et al. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer. 2007;97:761–768.
   PubMed Web of Science ®Google Scholar
• Ma L, Qiao H, He C, et al. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer. Invest New Drugs. 2012;30:508–517.
   PubMed Web of Science ®Google Scholar
• Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64:8604–8612.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 2004;64:8420–8427.
   PubMed Web of Science ®Google Scholar
• Ziarek JJ, Veldkamp CT, Zhang F, et al. Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus. J Biol Chem. 2013;288:737–746.
   PubMed Web of Science ®Google Scholar
• Veldkamp CT, Peterson FC, Pelzek AJ, et al. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci. 2005;14:1071–1081.
   PubMed Web of Science ®Google Scholar
• Alam F, Al-Hilal TA, Park J, et al. Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate). Biomaterials. 2016;86:56–67.
   PubMed Web of Science ®Google Scholar
• Handschin AE, Trentz OA, Hoerstrup SP, et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg. 2005;92:177–183.
   PubMed Web of Science ®Google Scholar
• Pollari S, Kakonen RS, Mohammad KS, et al. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res. 2012;10:597–604.
   PubMed Web of Science ®Google Scholar
• Boothello RS, Patel NJ, Sharon C, et al. A unique nonsaccharide mimetic of heparin hexasaccharide inhibits colon cancer stem cells via p38 MAP kinase activation. Mol Cancer Ther. 2019;18:51–61.
   PubMed Web of Science ®Google Scholar
• Kovacsovics TJ, Mims A, Salama ME, et al. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Adv. 2018;2:381–389.
   PubMed Web of Science ®Google Scholar
• Lin S-C,Wu C-PT, seng T, et al. Role of syndecan-1 and exogenous heparin in hepatoma sphere formation. Biochem Cell Biol. 2020;98(2):112-119.
   PubMedGoogle Scholar
• Sadaie RM. Can heparins stimulate bone cancer stem cells and interfere with tumorigenesis? Ther Adv Drug Saf. 2011;2:271–282.
   PubMedGoogle Scholar
• Sun H, Cao D, Wu H, et al. Development of low molecular weight heparin based nanoparticles for metastatic breast cancer therapy. Int J Biol Macromol. 2018;112:343–355.
   PubMed Web of Science ®Google Scholar
• Phillips PG, Yalcin M, Cui H, et al. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. 2011;31:411–419.
   PubMed Web of Science ®Google Scholar